Sapanisertib
- Generic Name
- Sapanisertib
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15N7O
- CAS Number
- 1224844-38-5
- Unique Ingredient Identifier
- JGH0DF1U03
- Background
Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.
Faeth Therapeutics Advances Novel Three-Pronged Approach for Metabolism-Driven Cancers with Promising Preclinical Results
• Faeth Therapeutics has published preclinical proof-of-concept data in the British Journal of Cancer supporting their multi-node PIKTOR approach, which combines dual PI3K/AKT/mTOR pathway inhibitors with an insulin-suppressing diet.
• The company's strategy targets cancer metabolism through simultaneous inhibition of multiple pathway nodes, showing tumor regression in endometrial and breast cancer models while potentially overcoming common resistance mechanisms.
• A Phase 2 trial in collaboration with The GOG Foundation is currently underway for patients with endometrial cancer, building on earlier clinical data that demonstrated an 80% objective response rate with the drug combination.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath